These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 24413733)

  • 1. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.
    Brastianos PK; Taylor-Weiner A; Manley PE; Jones RT; Dias-Santagata D; Thorner AR; Lawrence MS; Rodriguez FJ; Bernardo LA; Schubert L; Sunkavalli A; Shillingford N; Calicchio ML; Lidov HG; Taha H; Martinez-Lage M; Santi M; Storm PB; Lee JY; Palmer JN; Adappa ND; Scott RM; Dunn IF; Laws ER; Stewart C; Ligon KL; Hoang MP; Van Hummelen P; Hahn WC; Louis DN; Resnick AC; Kieran MW; Getz G; Santagata S
    Nat Genet; 2014 Feb; 46(2):161-5. PubMed ID: 24413733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas.
    Yoshimoto K; Hatae R; Suzuki SO; Hata N; Kuga D; Akagi Y; Amemiya T; Sangatsuda Y; Mukae N; Mizoguchi M; Iwaki T; Iihara K
    Neuropathology; 2018 Feb; 38(1):3-10. PubMed ID: 28840946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases.
    Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Suri V; Sarkar C; Jagdevan A; Sharma BS; Sharma MC
    J Neurooncol; 2017 Jul; 133(3):487-495. PubMed ID: 28500561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do craniopharyngioma molecular signatures correlate with clinical characteristics?
    Omay SB; Chen YN; Almeida JP; Ruiz-Treviño AS; Boockvar JA; Stieg PE; Greenfield JP; Souweidane MM; Kacker A; Pisapia DJ; Anand VK; Schwartz TH
    J Neurosurg; 2018 May; 128(5):1473-1478. PubMed ID: 28707994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Implication of BRAF V600E and CTNNB1 gene mutations in the pathological classification of craniopharyngioma].
    Xu SS; Wang LM; Zhao LH; He ZL; Gong LP; Lu DH; Teng LH
    Zhonghua Bing Li Xue Za Zhi; 2019 Sep; 48(9):682-687. PubMed ID: 31495087
    [No Abstract]   [Full Text] [Related]  

  • 6. BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma.
    Larkin SJ; Preda V; Karavitaki N; Grossman A; Ansorge O
    Acta Neuropathol; 2014; 127(6):927-9. PubMed ID: 24715106
    [No Abstract]   [Full Text] [Related]  

  • 7. [Craniopharyngiomas: The Dawn of a New Era with the Elucidation of Driver Genes].
    Fujio S; Hanaya R
    No Shinkei Geka; 2023 Sep; 51(5):917-928. PubMed ID: 37743344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles.
    Hölsken A; Sill M; Merkle J; Schweizer L; Buchfelder M; Flitsch J; Fahlbusch R; Metzler M; Kool M; Pfister SM; von Deimling A; Capper D; Jones DT; Buslei R
    Acta Neuropathol Commun; 2016 Feb; 4():20. PubMed ID: 26927026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature.
    Borrill R; Cheesman E; Stivaros S; Kamaly-Asl ID; Gnanalingham K; Kilday JP
    Childs Nerv Syst; 2019 Jan; 35(1):169-173. PubMed ID: 30069716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular defects in BRAF wild-type ameloblastomas and craniopharyngiomas-differences in mutation profiles in epithelial-derived oropharyngeal neoplasms.
    Bartels S; Adisa A; Aladelusi T; Lemound J; Stucki-Koch A; Hussein S; Kreipe H; Hartmann C; Lehmann U; Hussein K
    Virchows Arch; 2018 Jun; 472(6):1055-1059. PubMed ID: 29546640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PROP1 and CTNNB1 expression in adamantinomatous craniopharyngiomas with or without β-catenin mutations.
    Cani CM; Matushita H; Carvalho LR; Soares IC; Brito LP; Almeida MQ; Mendonça BB
    Clinics (Sao Paulo); 2011; 66(11):1849-54. PubMed ID: 22086512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Craniopharyngioma in Pediatrics and Adults.
    Piloni M; Gagliardi F; Bailo M; Losa M; Boari N; Spina A; Mortini P
    Adv Exp Med Biol; 2023; 1405():299-329. PubMed ID: 37452943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemistry or Molecular Analysis: Which Method Is Better for Subtyping Craniopharyngioma?
    Fukuhara N; Iwata T; Inoshita N; Yoshimoto K; Kitagawa M; Fukuhara H; Tatsushima K; Yamaguchi-Okada M; Takeshita A; Ito J; Takeuchi Y; Yamada S; Nishioka H
    Endocr Pathol; 2021 Jun; 32(2):262-268. PubMed ID: 32965631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted BRAF and CTNNB1 next-generation sequencing allows proper classification of nonadenomatous lesions of the sellar region in samples with limiting amounts of lesional cells.
    Marucci G; de Biase D; Zoli M; Faustini-Fustini M; Bacci A; Pasquini E; Visani M; Mazzatenta D; Frank G; Tallini G
    Pituitary; 2015 Dec; 18(6):905-11. PubMed ID: 26156055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of BRAF mutation status of craniopharyngioma using magnetic resonance imaging features.
    Yue Q; Yu Y; Shi Z; Wang Y; Zhu W; Du Z; Yao Z; Chen L; Mao Y
    J Neurosurg; 2018 Jul; 129(1):27-34. PubMed ID: 28984520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma.
    Goschzik T; Gessi M; Dreschmann V; Gebhardt U; Wang L; Yamaguchi S; Wheeler DA; Lauriola L; Lau CC; Müller HL; Pietsch T
    J Neuropathol Exp Neurol; 2017 Feb; 76(2):126-134. PubMed ID: 28069929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into pituitary tumorigenesis: from Sanger sequencing to next-generation sequencing and beyond.
    Shen AJJ; King J; Scott H; Colman P; Yates CJ
    Expert Rev Endocrinol Metab; 2019 Nov; 14(6):399-418. PubMed ID: 31793361
    [No Abstract]   [Full Text] [Related]  

  • 18. Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy.
    Martinez-Gutierrez JC; D'Andrea MR; Cahill DP; Santagata S; Barker FG; Brastianos PK
    Neurosurg Focus; 2016 Dec; 41(6):E2. PubMed ID: 27903124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-catenin mutations in craniopharyngiomas and pituitary adenomas.
    Oikonomou E; Barreto DC; Soares B; De Marco L; Buchfelder M; Adams EF
    J Neurooncol; 2005 Jul; 73(3):205-9. PubMed ID: 15980970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible linkage between specific histological structures and aberrant reactivation of the Wnt pathway in adamantinomatous craniopharyngioma.
    Kato K; Nakatani Y; Kanno H; Inayama Y; Ijiri R; Nagahara N; Miyake T; Tanaka M; Ito Y; Aida N; Tachibana K; Sekido K; Tanaka Y
    J Pathol; 2004 Jul; 203(3):814-21. PubMed ID: 15221941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.